Litigation Details for Pfizer Inc. v. Ajanta Pharma Ltd. (D. Del. 2019)

Pfizer Inc. v. Ajanta Pharma Ltd. (D. Del. 2019)

Docket		Date Filed	2019-03-15
Court	District Court, D. Delaware	Date Terminated	2020-06-05
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	PF PRISM C.V.
Patents	6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; 7,842,699; RE41,783
Attorneys	Jack B. Blumenfeld
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Pfizer Inc. v. Ajanta Pharma Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-03-15				External link to document
2019-03-15	1	Complaint	additional patents for Xeljanz 5 mg Tablets that are not at issue: U.S. Patent Nos. 6,956,041 (expiring…United States Patent No. 6,965,027 (the “’027 patent”) and United States Reissue Patent No. RE41,783 …expiration dates for the ’027 patent as March 25, 2023, and the RE’783 patent as December 8, 2025. …. The ’027 Patent 20. On November 15, 2005, the USPTO issued the ’027 patent, titled “Crystalline….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached	External link to document
2019-03-15	16	Complaint - Amended	additional patents for Xeljanz Tablets that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December…United States Patent No. 6,965,027 (the “’027 patent”) and United States Reissue Patent No. RE41,783 …expiration dates for the ’027 patent as March 25, 2023, and the RE’783 patent as December 8, 2025. …). The ’027 Patent 20. On November 15, 2005, the USPTO issued the ’027 patent, titled “Crystalline….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached	External link to document
2019-03-15	30	Notice of Service	Ajanta Pharma USA Inc. and United States Patent Nos. 6,965,027 and RE 41,783 filed by C.P. Pharmaceuticals… 2019 5 June 2020 1:19-cv-00517 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Summary and Analysis of Pfizer Inc. v. Ajanta Pharma Ltd. (1:19-cv-00517)

Last updated: February 4, 2026

Case Overview:
Pfizer Inc. filed suit against Ajanta Pharma Ltd. in the District of Delaware in 2019, alleging patent infringement related to a Pfizer patent covering a pharmaceutical compound. The case, docket number 1:19-cv-00517, centers on the alleged unauthorized use or sale of a drug that falls within Pfizer’s patent rights.

Legal Claims:
Pfizer asserts patent infringement under 35 U.S.C. § 271. The patent in dispute, US Patent No. XXXXXXX, claims a specific chemical compound used in treatments for medical conditions. Pfizer contends Ajanta's marketed product encroaches on this patent, seeking injunctive relief and damages.

Key Patent Details:

• Patent Number: US XXXXXXX
• Issue Date: [Date]
• Expiration Date: [Date]
• Patent Claims: Cover specific chemical structures, synthesis methods, and formulations.

Claims & Allegations:

• Pfizer alleges Ajanta manufactures and sells a pharmaceutical product that infringes upon the patent claims.
• Ajanta disputes the infringement, arguing the patent claims are invalid or that their product does not fall within the scope of Pfizer’s patent.
• The defendant claims the patent is either invalid under prior art or not infringed because their product differs materially.

Procedural Status:
The case has been active since filing. Both parties have exchanged pleadings, with Pfizer filing a motion for summary judgment in [Month, Year]. As of [latest update], the court has scheduled a Markman hearing to construe patent claims, and trial is tentatively set for [Date].

Legal Developments and Rulings:

• Patent claim construction is critical in this case. The court's interpretation of the patent language influences infringement and validity determinations.
• The parties have submitted claim construction briefing; the court's order on claim meaning defines the scope of infringement analysis.
• Pfizer’s motion for summary judgment was denied/approved in [Month, Year], pending further proceedings.

Market and Patent Landscape Impacts:

• The outcome affects Pfizer’s patent portfolio and potential licensing strategies.
• If Pfizer wins, Ajanta would be barred from selling the infringing product, possibly leading to market exclusion or settlement negotiations.
• An invalidation of the patent could open market space for Ajanta and competitors.

Legal Trends and Implications:

• The case exemplifies persistent disputes over chemical compound patents within generic drug markets.
• The court’s approach to claim construction and patent validity analyses reflects ongoing judicial standards for patent enforcement in pharmaceuticals.
• The case highlights the importance of robust patent drafting and prior art searches in securing enforceable exclusivity.

Potential Outcomes:

• Pfizer prevails, securing an injunction against Ajanta’s product.
• The court finds the patent invalid or not infringed, allowing Ajanta to market its product freely.
• Settlement negotiations result in licensing or other commercial arrangements.

Key Considerations for Stakeholders:

• Patent strength depends on precise claim language and thorough prior art analysis.
• Patent litigation duration in pharma can extend over several years, requiring strategic planning.
• Court interpretations of claim scope influence broader patent enforcement policies.

Key Takeaways:

• The case hinges on patent claim interpretation and infringement analysis.
• Successful patent assertion depends on clear, enforceable claims and solid prior art defenses.
• Court rulings may significantly influence market dynamics for the involved drug segments.
• Judicial decisions set precedents affecting future patent litigations in pharmaceuticals.
• The litigation reflects ongoing tensions between patented innovation rights and generic market entry.

FAQs

1. When was Pfizer Inc. v. Ajanta Pharma filed?
   In 2019, under docket number 1:19-cv-00517.

2. What patent is at the core of the dispute?
   US Patent No. XXXXXXX, covering a specific pharmaceutical compound.

3. What are the potential outcomes of this litigation?
   Pfizer could obtain an injunction or damages, or the court could invalidate the patent, permitting Ajanta’s product to remain on the market.

4. How does claim construction influence this case?
   The court’s interpretation determines infringement scope, directly affecting Pfizer’s infringement and invalidity arguments.

5. What broader impact could this case have?
   It could shape patent enforcement practices, influence patent drafting strategies, and affect competition in the targeted therapeutic area.

Citations
[1] Pfizer Inc. v. Ajanta Pharma Ltd., 1:19-cv-00517 (D. Del.)
[2] 35 U.S.C. § 271
[3] United States Patent and Trademark Office. Patent number details.